WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005117866) AMORPHOUS CLOPIDOGREL HYDROCHLORIDE AND ITS ANTITHROMBOTIC USE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/117866    International Application No.:    PCT/US2005/019326
Publication Date: 15.12.2005 International Filing Date: 01.06.2005
IPC:
A61K 31/4365 (2006.01), C07D 495/04 (2006.01), A61P 9/00 (2006.01)
Applicants: IVAX PHARMACEUTICALS S.R.O. [CZ/CZ]; Ostravska 29/305, 747 70 Opava-Komarov (CZ) (For All Designated States Except US).
KAZNAKOV, Vladimir [SK/SK]; (SK) (For US Only).
VEVERKOVA, Eva [SK/SK]; (SK) (For US Only).
VEVERKA, Miroslav [SK/SK]; (SK) (For US Only)
Inventors: KAZNAKOV, Vladimir; (SK).
VEVERKOVA, Eva; (SK).
VEVERKA, Miroslav; (SK)
Agent: FOLEY, Shawn, P.; Lerner, David, Littenberg, Krumholz & Mentlik, LLP, 600 South Avenue West, Westfield, New Jersey 07090-1497 (US)
Priority Data:
0412172.9 01.06.2004 GB
0418395.0 18.08.2004 GB
Title (EN) AMORPHOUS CLOPIDOGREL HYDROCHLORIDE AND ITS ANTITHROMBOTIC USE
(FR) HYDROCHLORURE DE CLOPIDOGREL AMORPHE ET SON UTILISATION EN TANT QU'ANTITHROMBOTIQUE
Abstract: front page image
(EN)The invention provides methyl (+)-(S)-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrochloride in amorphous form, processes for the preparation of the amorphous form and a pharmaceutical composition containing the amorphous form. The amorphous form is useful as a blood platelet aggregation inhibitor and as an antithrombotic agent.
(FR)L'invention concerne un hydrochlorure de méthyl (+)-(S)-(2-chlorophényl)-6,7-dihydrothiéno[3,2-c]pyridine-5(4H)-acétate de forme amorphe, des procédés permettant de préparer cette forme amorphe, et une composition pharmaceutique contenant cette forme amorphe. Cette forme amorphe est utile en tant qu'inhibiteur de l'agrégation des plaquettes sanguines, et en tant qu'agent antithrombotique.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)